AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32773325 — intervention group
Group type: COMPARATOR
Intervention: Base substrate (N)
Number of subjects: 168
Study 32773325 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between A and B
Number of subjects: 168
Study 32773325 — intervention group
Group type: COMPARATOR
Intervention: Usability of N and B
Number of subjects: 168
Study 34162704 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic biodiversity losses (drought-driven species losses)
Number of subjects: 0
Study 34162704 — intervention group
Group type: COMPARATOR
Intervention: Randomized biodiversity losses
Number of subjects: 0
Study 34162704 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic biodiversity losses
Number of subjects: 0
Study 34454580 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs) at maximum tolerated daily dose
Number of subjects: 0
Study 34454580 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 34454580 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 35966092 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term acupoint stimulation (LAS)
Number of subjects: 84
Study 35966092 — intervention group
Group type: COMPARATOR
Intervention: Sham LAS (SLAS)
Number of subjects: 84
Study 32208960 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m2, days 1, 8, and 15, every 4 weeks)
Number of subjects: 91
Study 32208960 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with trastuzumab (PT; initially 8 mg/kg followed by 6 mg/kg, every 3 weeks)
Number of subjects: 91
Study 33498461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (moderate calorie-restricted diet, increased physical activity, nutritional education)
Number of subjects: 29
Study 33498461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 29
Study 32370147 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on healthy drinking behavior and promotion of water consumption
Number of subjects: 250
Study 32370147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 250
Study 35565061 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback report on employability scores and job crafting suggestions
Number of subjects: 165
Study 35565061 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 165
Study 32868580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 252 mg·kg BW-1)
Number of subjects: 6
Study 32868580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 752 mg·kg BW-1)
Number of subjects: 6
Study 32868580 — intervention group
Group type: COMPARATOR
Intervention: Bitter flavored water (control)
Number of subjects: 6
Study 35225392 — intervention group
Group type: EXPERIMENTAL
Intervention: True air filtration (stand-alone HEPA air cleaners and MERV 16 filters)
Number of subjects: 172
Study 35225392 — intervention group
Group type: COMPARATOR
Intervention: Sham air filtration
Number of subjects: 172
Study 33563102 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Number of subjects: 36
Study 33563102 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Number of subjects: 36
Study 33563102 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterless method (natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Number of subjects: 36
Study 33563102 — intervention group
Group type: COMPARATOR
Intervention: Two-stage method (4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Number of subjects: 36
Study 33563102 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterless method
Number of subjects: 36
Study 33563102 — intervention group
Group type: COMPARATOR
Intervention: Two-stage method
Number of subjects: 36
Study 33789001 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Number of subjects: 0
Study 33789001 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of triheptanoin
Number of subjects: 0
Study 33789001 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased triheptanoin dose levels
Number of subjects: 0
Study 36282072 — intervention group
Group type: EXPERIMENTAL
Intervention: High loads IMT
Number of subjects: 26
Study 36282072 — intervention group
Group type: COMPARATOR
Intervention: Low loads IMT
Number of subjects: 26
Study 32464489 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation)
Number of subjects: 92
Study 32464489 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg per day for 6 weeks)
Number of subjects: 92
Study 35775284 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2 (treatment group)
Number of subjects: 1231
Study 35775284 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2 (control group)
Number of subjects: 1231
Study 33984021 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepfake text detection methods (13 methods evaluated)
Number of subjects: 25572
Study 34951042 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor‐aspirin
Number of subjects: 6412
Study 34951042 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel‐aspirin
Number of subjects: 6412
Study 34951042 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 6412
Study 33371098 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study 33371098 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 35583845 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Machine (GBM)
Number of subjects: 9478
Study 35583845 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 9478
Study 33932465 — intervention group
Group type: EXPERIMENTAL
Intervention: CHECKS protocol
Number of subjects: 658
Study 35522139 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy including bevacizumab
Number of subjects: 153
Study 35522139 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy in patients with RAS/BRAF mutation
Number of subjects: 153
Study 35522139 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic assessment by three radiologists
Number of subjects: 153
Study 35522139 — intervention group
Group type: COMPARATOR
Intervention: RECIST 1.1 measurements
Number of subjects: 153
Study 33187488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tuberculosis
Number of subjects: 415
Study 33187488 — intervention group
Group type: EXPERIMENTAL
Intervention: Being on re‐treatment for tuberculosis
Number of subjects: 415
Study 33187488 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged ≥45 years
Number of subjects: 415
Study 33187488 — intervention group
Group type: EXPERIMENTAL
Intervention: Having poor social support
Number of subjects: 415
Study 33187488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis/Human Immunodeficiency Virus (TB/HIV) co‐infection
Number of subjects: 415
Study 35357078 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily, oral, tablets)
Number of subjects: 32
Study 35357078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32989895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 88
Study 32989895 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)
Number of subjects: 88
Study 32989895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 88
Study 32989895 — intervention group
Group type: COMPARATOR
Intervention: Control (Adper Single Bond 2 without additional treatment)
Number of subjects: 88
Study 35345383 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered education intervention (individual training in two one-hour sessions)
Number of subjects: 30
Study 35345383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33183059 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein (IJV) approach
Number of subjects: 200
Study 33183059 — intervention group
Group type: COMPARATOR
Intervention: Axillary vein/subclavian vein (AxV/SCV) approach
Number of subjects: 200
Study 33183059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IJV and AxV/SCV approaches
Number of subjects: 200
Study 36372094 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tACS
Number of subjects: 11
Study 36372094 — intervention group
Group type: COMPARATOR
Intervention: γ-tACS
Number of subjects: 11
Study 36372094 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 11
Study 34535330 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of remifentanil starting at 0.1 mcg/kg/min, increased to 1 mcg/kg/min if required
Number of subjects: 92
Study 34535330 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus patient-controlled sedation analgesia (PCSA) with remifentanil infusion at 0.05 mcg/kg per minute and bolus of 0.1 mcg/kg with lock-out time of 3 minutes
Number of subjects: 92
Study 32883706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear acquisition training followed by eyeblink CR acquisition (Group 1)
Number of subjects: 100
Study 32883706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear acquisition training followed by eyeblink CR acquisition (Group 2)
Number of subjects: 100
Study 32883706 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear acquisition training followed by eyeblink CR acquisition (Group 3)
Number of subjects: 100
Study 32883706 — intervention group
Group type: COMPARATOR
Intervention: Control condition testing fear conditioning only (Group 4)
Number of subjects: 100
Study 32883706 — intervention group
Group type: COMPARATOR
Intervention: Control condition testing eyeblink conditioning only (Group 5)
Number of subjects: 100
Study 36307873 — intervention group
Group type: EXPERIMENTAL
Intervention: ICL/TICL (toric ICL)
Number of subjects: 300
Study 36307873 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 300
Study 34753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream
Number of subjects: 88
Study 34753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Number of subjects: 88
Study 34753154 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbuffered lidocaine needle‐free injection
Number of subjects: 88
Study 34420958 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multi‐disciplinary perioperative pathway
Number of subjects: 692
Study 34420958 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care practices
Number of subjects: 692
Study 32376628 — intervention group
Group type: EXPERIMENTAL
Intervention: ELX-02 (0.3-7.5 mg/kg)
Number of subjects: 0
Study 32376628 — intervention group
Group type: EXPERIMENTAL
Intervention: ELX-02 (20 and 100 μg/ml)
Number of subjects: 0
Study 32376628 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 35521810 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown yogurt (SSN)
Number of subjects: 70
Study 35521810 — intervention group
Group type: COMPARATOR
Intervention: Standard probiotic-containing yogurt (YJD)
Number of subjects: 70
Study 35521810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 33501904 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mL of water
Number of subjects: 180
Study 33501904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 donut
Number of subjects: 180
Study 33501904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted
Number of subjects: 180
Study 35703097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified care (≥8 outpatient visits over 2 years)
Number of subjects: 1771
Study 35703097 — intervention group
Group type: COMPARATOR
Intervention: Conventional care alone
Number of subjects: 1771
Study 616747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Past depression vignette
Number of subjects: 440
Study 616747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Past suicide attempt vignette
Number of subjects: 440
Study 616747691 — intervention group
Group type: EXPERIMENTAL
Intervention: Death by suicide vignette
Number of subjects: 440
Study 616747691 — intervention group
Group type: COMPARATOR
Intervention: No information on suicide or mental illness (control)
Number of subjects: 440
Study 34923285 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg plus methotrexate (MTX)
Number of subjects: 0
Study 34923285 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 0
Study 34376358 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%)
Number of subjects: 174
Study 34376358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 174
Study 35557481 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness-based contraceptive counselling (EBCC)
Number of subjects: 57
Study 35557481 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid referral pathways
Number of subjects: 57
Study 35557481 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in EBCC
Number of subjects: 57
Study 33028796 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinding - diamond bur
Number of subjects: 120
Study 33028796 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasion - aluminum oxide particles
Number of subjects: 120
Study 33028796 — intervention group
Group type: EXPERIMENTAL
Intervention: Liner - application of a ceramic liner (IPS e.max Zirliner, Ivoclar Vivadent)
Number of subjects: 120
Study 33028796 — intervention group
Group type: COMPARATOR
Intervention: Control (no surface treatment)
Number of subjects: 120
Study 33028796 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling (12,000 thermal cycles; 5-55ºC)
Number of subjects: 120
Study 33028796 — intervention group
Group type: EXPERIMENTAL
Intervention: No thermocycling
Number of subjects: 120
Study 33155295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with supplemental oxygen (10 L/min)
Number of subjects: 29
Study 33155295 — intervention group
Group type: COMPARATOR
Intervention: Exercise training with medical air (10 L/min)
Number of subjects: 29
Study 32694412 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts ≤200 cells/μl
Number of subjects: 2499
Study 34082804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory app usage
Number of subjects: 200
Study 34082804 — intervention group
Group type: EXPERIMENTAL
Intervention: Facultative app usage
Number of subjects: 200
Study 34082804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app)
Number of subjects: 200
Study 32295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill for prevention of cardiovascular disease in the PolyIran trial
Number of subjects: 0
Study 32295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for HIV self-testing and follow-up in the PASTAL trial
Number of subjects: 0
Study 32295604 — intervention group
Group type: COMPARATOR
Intervention: Locally available care as a comparator
Number of subjects: 0
Study 32295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to effective interventions post-trial
Number of subjects: 0
Study 32295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics education and capacity building
Number of subjects: 0
Study 35153076 — intervention group
Group type: COMPARATOR
Intervention: HCS (two 2.5-mm headless compression screws)
Number of subjects: 20
Study 35153076 — intervention group
Group type: EXPERIMENTAL
Intervention: HCS + BP (two 2.5-mm headless compression screws augmented with a 2.4-mm buttress plate)
Number of subjects: 20
Study 35854670 — intervention group
Group type: EXPERIMENTAL
Intervention: Music training for 3 months
Number of subjects: 0
Study 35854670 — intervention group
Group type: COMPARATOR
Intervention: Visual art training for 3 months
Number of subjects: 0
Study 35854670 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33487258 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate feeding (30 kcal/kg/day, 0.25 gN/kg/day)
Number of subjects: 104
Study 33487258 — intervention group
Group type: COMPARATOR
Intervention: Low rate feeding (15 kcal/day, 0.125 gN/kg/day)
Number of subjects: 104
Study 33487258 — intervention group
Group type: EXPERIMENTAL
Intervention: High rate feeding
Number of subjects: 104
Study 33487258 — intervention group
Group type: COMPARATOR
Intervention: Low rate feeding
Number of subjects: 104
Study 35389920 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based mobile health app intervention
Number of subjects: 132
Study 35389920 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 132
Study 33426970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 22
Study 33426970 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 35737665 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-Step intervention
Number of subjects: 569
Study 32988930 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel lifts
Number of subjects: 100
Study 32988930 — intervention group
Group type: COMPARATOR
Intervention: Calf muscle eccentric exercise
Number of subjects: 100
Study 32988930 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 100
Study 36219061 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole 2% ointment with weekly email surveys for 6 weeks, then monthly for 12 months (intervention group)
Number of subjects: 28
Study 36219061 — intervention group
Group type: COMPARATOR
Intervention: Crisaborole 2% ointment without email surveys (control group)
Number of subjects: 28
Study 34039133 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour clinical shift
Number of subjects: 0
Study 34039133 — intervention group
Group type: COMPARATOR
Intervention: 6-hour clinical shift
Number of subjects: 0
Study 33142117 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral axons release serine (Ser) to support growth of exSer-dependent PDAC cells during Ser/Gly deprivation.
Number of subjects: 0
Study 33142117 — intervention group
Group type: EXPERIMENTAL
Intervention: ExSer-dependent PDAC tumors in mice on a Ser/Gly-free diet.
Number of subjects: 0
Study 33142117 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of compensatory neuronal innervation using LOXO-101, a Trk-NGF inhibitor.
Number of subjects: 0
Study 33794962 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Repetitive Behaviours (MRB) parent group intervention
Number of subjects: 250
Study 33794962 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation parent group Learning About Autism (LAA)
Number of subjects: 250
Study 32704168 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Intelligence Learning Optimizer (MILO)
Number of subjects: 211
Study 32704168 — intervention group
Group type: COMPARATOR
Intervention: Non-automated ML approach
Number of subjects: 211
Study 32704168 — intervention group
Group type: COMPARATOR
Intervention: Traditional multivariate logistic regression (LR)
Number of subjects: 211
Study 35469509 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS without CPD
Number of subjects: 279
Study 35469509 — intervention group
Group type: COMPARATOR
Intervention: CAS with CPD
Number of subjects: 279
Study 34195261 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicium verum mouthwash (group A)
Number of subjects: 50
Study 34195261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 50
Study 32434884 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA rebound in semen
Number of subjects: 12
Study 32434884 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA levels in semen
Number of subjects: 12
Study 32434884 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA molecular diversity
Number of subjects: 12
Study 32434884 — intervention group
Group type: EXPERIMENTAL
Intervention: Compartmentalization of viral rebound
Number of subjects: 12
Study 35113644 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HPA-axis functioning
Number of subjects: 151
Study 35113644 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-axis recovery
Number of subjects: 151
Study 33128722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (IDX) using a cycle ergometer for 60 min during each OL‐HDF session
Number of subjects: 12
Study 33128722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (IDX)
Number of subjects: 12
Study 33128722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 33227001 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration through a polyethersulfone membrane
Number of subjects: 64
Study 33227001 — intervention group
Group type: COMPARATOR
Intervention: Nonhemofiltered group
Number of subjects: 64
Study 33227001 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration
Number of subjects: 64
Study 36442896 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism Surveillance Pathway (ASP)
Number of subjects: 12
Study 36442896 — intervention group
Group type: COMPARATOR
Intervention: Surveillance as Usual (SaU)
Number of subjects: 12
Study 34101496 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of 61.6 Gy to the primary tumor
Number of subjects: 260
Study 34101496 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) of 50.4 Gy to the tumor and regional lymph nodes
Number of subjects: 260
Study 32331010 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ/SAM 10/10 mg, 20/20 mg, 30/30 mg
Number of subjects: 100
Study 32331010 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 100
Study 35505117 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model using PCAT radiomics and Fat Attenuation Index (FAI)
Number of subjects: 210
Study 35505117 — intervention group
Group type: COMPARATOR
Intervention: Fat Attenuation Index (FAI) model
Number of subjects: 210
Study 33877063 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexHD Pliable
Number of subjects: 230